Impala Nordic comments on OncoZenge AB (publ) (“OncoZenge” or the “Company”) latest news regarding the expanded agreement with its strategic partner Molteni Farmaceutici (“Molteni”), covering commercial-scale manufacturing of BupiZenge™ for Europe. Under the updated agreement, Molteni assumes responsibility for high-volume, commercial manufacturing of BupiZenge™ for the European market, providing a partner-based route for commercial supply. The expanded agreement shifts much of the operational complexity and uncertainty in manufacturing, quality and logistics to an established European pharmaceutical actor and is consistent with OncoZenge’s capital-light operating model. With key external partners now in place across clinical development and commercial supply, remaining drivers in the investment case are increasingly concentrated to clinical and regulatory outcomes. 

Read the full comment here.

For additional information, please contact:

Charlie Dahlström, Equity Research Analystcharlie@impalanordic.se

About Impala Nordic

Impala Nordic provides company analysis, coverage, and comprehensive investor relations (IR) services. The portfolio includes listed small-cap companies, where Impala Nordic acts as a communicative bridge between the companies and investors.

The material produced by Impala Nordic is independent but sponsored. This means that Impala Nordic has received payment from the client to produce the analysis and coverage. The client has not been able to influence Impala Nordic’s opinions expressed in the material.

Bifogade filer

Coverage OncoZenge 251204